We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Goes Too Far in GDUFA II Draft Guidance, AAM Says
FDA Goes Too Far in GDUFA II Draft Guidance, AAM Says
An FDA policy proposal on expedited generic drug approvals runs counter to the goals of the program and breaks faith with the upcoming GDUFA II agreement with the industry, generic drugmakers said.